390 related articles for article (PubMed ID: 32844745)
1. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
2. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
Li GL; Ding GX; Zeng L; Ming SL; Fu PF; Wang Q; Yang GY; Wang J; Chu BB
J Virol; 2021 Jul; 95(16):e0076021. PubMed ID: 34037418
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation.
Wang S; Han L; Han J; Li P; Ding Q; Zhang QJ; Liu ZP; Chen C; Yu Y
Nat Chem Biol; 2019 Dec; 15(12):1223-1231. PubMed ID: 31659317
[TBL] [Abstract][Full Text] [Related]
5. Avoid the trap: Targeting PARP1 beyond human malignancy.
Kim C; Chen C; Yu Y
Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
[TBL] [Abstract][Full Text] [Related]
6. Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
Chen HD; Chen CH; Wang YT; Guo N; Tian YN; Huan XJ; Song SS; He JX; Miao ZH
Int J Cancer; 2019 Aug; 145(3):714-727. PubMed ID: 30675909
[TBL] [Abstract][Full Text] [Related]
7. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
8. PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
Kim C; Wang XD; Jang S; Yu Y
Biochem Biophys Res Commun; 2023 Feb; 646():78-85. PubMed ID: 36706709
[TBL] [Abstract][Full Text] [Related]
9. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
10. PARP mediated DNA damage response, genomic stability and immune responses.
Zong C; Zhu T; He J; Huang R; Jia R; Shen J
Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
[TBL] [Abstract][Full Text] [Related]
11. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
[TBL] [Abstract][Full Text] [Related]
12. PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
Ding X; Zhu Z; Lapek J; McMillan EA; Zhang A; Chung CY; Dubbury S; Lapira J; Firdaus S; Kang X; Gao J; Oyer J; Chionis J; Rollins RA; Li L; Niessen S; Bagrodia S; Zhang L; VanArsdale T
Sci Rep; 2022 Jul; 12(1):12501. PubMed ID: 35864202
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
[TBL] [Abstract][Full Text] [Related]
15. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
16. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells.
Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R
Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646
[TBL] [Abstract][Full Text] [Related]
17. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
Li P; Zhen Y; Kim C; Liu Z; Hao J; Deng H; Deng H; Zhou M; Wang XD; Qin T; Yu Y
Sci Adv; 2023 Oct; 9(43):eadg7752. PubMed ID: 37878693
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
McLaughlin LJ; Stojanovic L; Kogan AA; Rutherford JL; Choi EY; Yen RC; Xia L; Zou Y; Lapidus RG; Baylin SB; Topper MJ; Rassool FV
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17785-17795. PubMed ID: 32651270
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
20. Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
Zhang H; Lin X; Zha S
Biochem Soc Trans; 2022 Aug; 50(4):1169-1177. PubMed ID: 35959996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
